eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
vol. 30

Case report
Acneiform rash during lung cancer therapy with erlotinib (Tarceva®)

Agnieszka Owczarczyk-Saczonek
Henryk Witmanowski
Waldemar Placek

Postep Derm Alergol 2013; XXX, 3: 195–198
Online publish date: 2013/06/20
View full text Get citation
Tyrosine kinase inhibitors are currently applied in the treatment of non-small cell lung cancer with overexpressed epidermal growth factor receptor (EGFR). Acneiform rash is the earliest and most characteristic side effect of EGFR inhibition. The incidence may be as high as 50-100% of cases. We report a case of a 47-year-old patient who developed acneiform rash after 1.5 weeks of treatment with erlotinib.

acneiform-rash, erlotynib, tyrosine kinase inhibitors

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.